Placebo + DUPILUMAB for eczema

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 May 2013: Trial registered, NCT01859988

The trials

NCT01859988: Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

State
Completed
Phase
Phase 2
People
380 taking part
Started
May 2013
Primary completion
May 2014
Arms
Dupilumab 300 mg q2w, Dupilumab 200 mg q2w, Dupilumab 300 mg q4w, Dupilumab 100 mg q4w
Results
Posted on the registry
Papers
doi:10.1001/jamadermatol.2022.6192, doi:10.1016/j.jaad.2015.10.043, doi:10.1016/j.jaad.2016.04.054, doi:10.1016/s0140-6736(15)00388-8, doi:10.1097/der.0000000000000698, doi:10.1111/cts.13363
  1. 22 May 2013: Trial registered
  2. 28 Aug 2017: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.